REUN Stock Overview
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Reunion Neuroscience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.12 |
| 52 Week High | CA$7.62 |
| 52 Week Low | CA$0.63 |
| Beta | 4.21 |
| 1 Month Change | 0.90% |
| 3 Month Change | 45.47% |
| 1 Year Change | -72.96% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.05% |
Recent News & Updates
Shareholder Returns
| REUN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.9% | 0.2% | 1.0% |
| 1Y | -73.0% | 8.4% | 21.8% |
Return vs Industry: REUN underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: REUN underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| REUN volatility | |
|---|---|
| REUN Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: REUN's share price has been volatile over the past 3 months.
Volatility Over Time: REUN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 16 | Greg Mayes | reunionneuro.com |
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company’s lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications.
Reunion Neuroscience Inc. Fundamentals Summary
| REUN fundamental statistics | |
|---|---|
| Market cap | US$12.47m |
| Earnings (TTM) | -US$28.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs REUN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REUN income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$38.10m |
| Earnings | -CA$38.10m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did REUN perform over the long term?
See historical performance and comparison